Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

Elevation Oncology to discontinue development of EO-3021, a Claudin 18.2 ADC to treat advanced unresectable or metastatic gastric and GEJ: Boston Saturday, March 22, 2025, 15:00 H ...

Elevation Oncology (ELEV) announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug ...

Wedbush downgraded Elevation Oncology (ELEV) to Neutral from Outperform with a price target of $1.60, down from $5, after the company announced ...

Elevation Oncology has decided to discontinue development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC) which was ...

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on ...

The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.

Elevation Oncology is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the ...

Elevation Oncology ends EO-3021 development after Phase 1 results, shifts focus to EO-1022, and plans a major workforce ...

Wall Street cut rating on Elevation Oncology Inc (NASDAQ:ELEV) after the company announced it will discontinue development of its lead asset, EO-3021, due to disappointing efficacy in a Phase 1 trial.

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...